Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

PSA failure and the risk of death in prostate cancer patients treated with radiotherapy: in regard to Kwan et al. (Int J Radiat Oncol Biol Phys 2004;60:1040-1046).

Williams S.

Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1253-4; author reply 1254. No abstract available.

PMID:
15990030
2.

In regard to D'Amico et al.: predictors of mortality after prostate-specific antigen failure (Int J Radiat Oncol Biol Phys 2006;65:656-660).

Williams S.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1598; author reply 1598-9. No abstract available.

PMID:
17126225
3.

Comment on dose escalation and biochemical failure in prostate cancer: in regard to Kuban et al. (Int J Radiat Oncol Biol Phys 2008;70:67-74).

Schulz RJ, Kagan AR.

Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1288; author reply 1288-9. doi: 10.1016/j.ijrobp.2008.03.022. No abstract available.

PMID:
18572089
4.

Commentary on dose escalation and biochemical failure in prostate cancer: in regard to Eade et al. (Int. J. Radiat. Oncol. Biol. Phys. 2007;68:682-689).

Schulz RJ, Kagan AR.

Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):645; author reply 645-6. doi: 10.1016/j.ijrobp.2007.08.037. No abstract available.

PMID:
18207038
7.

Brachytherapy doses for prostate cancer customized to risk factors: is it more important "how much" or "where"? In regard to Stone et al. (Int J Radiat Oncol Biol Phys 2007;69:1472-1477).

Oton CA, Oton F.

Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):962; author reply 962-3. doi: 10.1016/j.ijrobp.2008.02.039. No abstract available.

PMID:
18514795
8.

Radiation dose is predictive of biochemical failure, local failure, and distant metastases. In regard to Kupelian et Al. (Int J Radiat Oncol Biol Phys 2008;71:16-22).

Kelly P.

Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1621-2; author reply 1622. doi: 10.1016/j.ijrobp.2008.08.030. No abstract available.

PMID:
19028291
9.
10.

In regard to Kupelian et al.: impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. IJROBP 2002;52:704-711.

Kwan W, Pickles T.

Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1577-9; author reply 1579. No abstract available.

PMID:
12459394
11.

Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.

Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.

Urology. 2008 Jan;71(1):136-40. doi: 10.1016/j.urology.2007.08.028.

PMID:
18242382
12.

The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.

See WA, Tyrrell CJ; CASODEX Early Prostate Cancer Trialists' Group.

J Cancer Res Clin Oncol. 2006 Aug;132 Suppl 1:S7-16.

PMID:
16896884
13.

In regard to Trofimov et al.: Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison (Int J Radiat Oncol Biol Phys 2007;69:444-453).

Albertini F, Lomax AJ, Hug EB.

Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1333-4; author reply 1334-5. No abstract available.

PMID:
17967323
14.

Predicting the risk of pelvic node involvement in men with prostate cancer in the contemporary era: change you can believe?: in regard to Yu, et al. (Int J Radiat Oncol Biol Phys in press).

Hayes M, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1598; author reply 1598-9. doi: 10.1016/j.ijrobp.2010.11.008. No abstract available.

PMID:
21414516
15.

Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control.

Stock RG, Ho A, Cesaretti JA, Stone NN.

Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):389-94.

PMID:
16965991
16.

Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.

Wo JY, Chen MH, Nguyen PL, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV.

J Clin Oncol. 2009 Dec 10;27(35):6000-5. doi: 10.1200/JCO.2009.23.6067. Epub 2009 Oct 26.

PMID:
19858385
17.

In regards to Thames et al.: increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. (Int J Radiat Oncol Biol Phys 2006;65:975-981).

Pickles T, Williams SG.

Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):318-9; author reply 319. No abstract available.

PMID:
17189080
18.

In regard to Chen et Al. (Int J Radiat Oncol Biol Phys 2007;69:25-31) and Chao et Al. (Int j Radiat Oncol Biol Phys 2007;69:32-40).

Yaeger TE.

Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):317; author reply 317-8. doi: 10.1016/j.ijrobp.2008.01.013. No abstract available.

PMID:
18406902
19.

Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.

Macdonald OK, Lee RJ, Snow G, Lee CM, Tward JD, Middleton AW, Middleton GW, Sause WT.

Urology. 2007 Feb;69(2):295-9.

PMID:
17320667
20.

In regard to Fiorino et al.: Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer (Int J Radiat Oncol Biol Phys 2003;57:953-962).

Bauman G, Rodrigues G.

Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):912-4; author reply 914-5. Review. No abstract available.

PMID:
15183497

Supplemental Content

Support Center